[{"address1": "Portway Building", "address2": "Blocks A & B Granta Park Great Abington", "city": "Cambridge", "zip": "CB21 6GS", "country": "United Kingdom", "phone": "44 1223 261 503", "website": "https://www.bicycletherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.", "fullTimeEmployees": 305, "companyOfficers": [{"maxAge": 1, "name": "Dr. Kevin  Lee M.B.A., Ph.D.", "age": 57, "title": "CEO & Executive Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 1497559, "exercisedValue": 0, "unexercisedValue": 3450590}, {"maxAge": 1, "name": "Mr. Alistair  Milnes", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 909050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Michael Charles-Ferguson Hannay", "age": 59, "title": "Chief Product & Supply Chain Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 698383, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christian  Heinis", "title": "Scientific Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Travis  Thompson", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Skynner B.sc. Ph.d., Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 881008, "exercisedValue": 0, "unexercisedValue": 6190095}, {"maxAge": 1, "name": "Ms. Stephanie  Yao", "title": "Senior Vice President of Investor Relations and Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zafar  Qadir", "title": "Chief Legal Officer & General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gillian  Langford Ph.D.", "title": "Head of Clinical and Project Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Phil  Jeffrey", "title": "Senior VP of Pre-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.54, "open": 5.46, "dayLow": 5.31, "dayHigh": 5.485, "regularMarketPreviousClose": 5.54, "regularMarketOpen": 5.46, "regularMarketDayLow": 5.31, "regularMarketDayHigh": 5.485, "payoutRatio": 0.0, "beta": 1.641, "forwardPE": -1.4588426, "volume": 280927, "regularMarketVolume": 280927, "averageVolume": 310450, "averageVolume10days": 544400, "averageDailyVolume10Day": 544400, "bid": 5.34, "ask": 5.39, "bidSize": 1, "askSize": 1, "marketCap": 372505600, "fiftyTwoWeekLow": 5.18, "fiftyTwoWeekHigh": 13.11, "allTimeHigh": 62.075, "allTimeLow": 5.18, "priceToSalesTrailing12Months": 13.144628, "fiftyDayAverage": 6.656, "twoHundredDayAverage": 7.43915, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -270076384, "profitMargins": 0.0, "sharesOutstanding": 49929952, "sharesShort": 1988977, "sharesShortPriorMonth": 1993719, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0287, "heldPercentInsiders": 0.01398, "heldPercentInstitutions": 0.82982004, "shortRatio": 8.0, "shortPercentOfFloat": 0.0517, "impliedSharesOutstanding": 69367896, "bookValue": 8.924, "priceToBook": 0.6017481, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -250660000, "trailingEps": -3.62, "forwardEps": -3.681, "enterpriseToRevenue": -9.53, "enterpriseToEbitda": 0.954, "52WeekChange": -0.5690789, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 5.37, "targetHighPrice": 44.0, "targetLowPrice": 6.0, "targetMeanPrice": 18.8, "targetMedianPrice": 15.0, "recommendationMean": 1.83333, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 648324992, "totalCashPerShare": 9.346, "ebitda": -283230016, "totalDebt": 5743000, "quickRatio": 10.329, "currentRatio": 10.664, "totalRevenue": 28339000, "debtToEquity": 0.929, "revenuePerShare": 0.409, "returnOnAssets": -0.2059, "returnOnEquity": -0.34585, "grossProfits": -210900992, "freeCashflow": -140091120, "operatingCashflow": -239724992, "revenueGrowth": 3.385, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -5.58642, "financialCurrency": "USD", "symbol": "BCYC", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Bicycle Therapeutics plc", "longName": "Bicycle Therapeutics plc", "epsTrailingTwelveMonths": -3.62, "epsForward": -3.681, "epsCurrentYear": -3.88182, "priceEpsCurrentYear": -1.3833717, "fiftyDayAverageChange": -1.2860003, "fiftyDayAverageChangePercent": -0.19320917, "twoHundredDayAverageChange": -2.06915, "twoHundredDayAverageChangePercent": -0.27814335, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1771621804, "regularMarketTime": 1771621203, "exchange": "NMS", "messageBoardId": "finmb_72510621", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -3.06859, "regularMarketPrice": 5.37, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1558618200000, "postMarketChangePercent": 0.0, "postMarketPrice": 5.37, "postMarketChange": 0.0, "regularMarketChange": -0.17, "regularMarketDayRange": "5.31 - 5.485", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 310450, "fiftyTwoWeekLowChange": 0.19000006, "fiftyTwoWeekLowChangePercent": 0.036679547, "fiftyTwoWeekRange": "5.18 - 13.11", "fiftyTwoWeekHighChange": -7.74, "fiftyTwoWeekHighChangePercent": -0.590389, "fiftyTwoWeekChangePercent": -56.90789, "earningsTimestampStart": 1771939800, "earningsTimestampEnd": 1771939800, "isEarningsDateEstimate": true, "displayName": "Bicycle Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]